



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

The Immunology of Bovine Respiratory Disease

Recent Advancements



Jodi L. McGill, MS, PhD^{a,*}, Randy E. Sacco, PhD^b

KEYWORDS

- Bovine • Respiratory disease • Lung • Innate immunity • Adaptive immunity
- Immunomodulation

KEY POINTS

- Bovine respiratory disease (BRD) is a syndrome caused by multiple factors, including environmental and management-related stressors and multiple viral and bacterial pathogens.
- The innate immune system is the first line of defense against BRD. Epithelial cells and immune sentinel cells prevent infection through mucociliary action and secretion of antimicrobial molecules, and secretion of proinflammatory cytokines.
- Neutrophils are essential for eliminating bacterial infections but also play an important role in the pathogenesis of BRD by contributing to lung tissue destruction and inflammation.
- After infection, cattle mount antibody and antigen-specific T-cell responses; however, pathogens frequently evade these immune responses using multiple strategies.
- Immunomodulation and innate training are future alternatives to antibiotics for the prevention and control of BRD.

INTRODUCTION

Susceptibility to bovine respiratory disease (BRD) is multifactorial, influenced by a complex interaction between stress, multiple viral and bacterial pathogens, and the host immune response (**Table 1**). Despite the widespread availability of vaccines and antimicrobial compounds, BRD remains a leading cause of morbidity, mortality, and economic loss to the cattle industry. The continued high prevalence of the disease underlines a fundamental gap in understanding of the host immune response to respiratory infection. In recent years, several advancements have been made in the

^a Department of Veterinary Microbiology and Preventative Medicine, Iowa State University, 1907 ISU C-Drive, VMRI Building 5, Ames, IA 50010, USA; ^b Ruminant Diseases and Immunology Research Unit, Agricultural Research Services, USDA, PO Box 70, 1920 Dayton Avenue, Ames, IA 50010, USA

* Corresponding author.

E-mail address: jlmcgill@iastate.edu

Table 1 The multiple factors with a role in bovine respiratory disease		
Stress Factors	Viral Agents	Bacterial Agents
Heat	PIV type 3	<i>M haemolytica</i>
Cold	BHV-1, BHV-4	<i>P multocida</i>
Dampness	BVDV	<i>H somni</i>
Dust	BRSV	<i>Mycoplasma bovis</i>
Injury	Adenovirus	<i>Trueperella pyogenes</i>
Fatigue	Coronavirus	
Dehydration	Enterovirus	
Nutritional	Reovirus	
Weaning	Influenza D virus	
Shipping		

understanding of the immune system's role in protecting—and potentially harming—the host and how multiple pathogens of the BRD complex interact to evade the host response. There have been comprehensive reviews on the immune response to BRD in previous issues of *Veterinary Clinics of North America: Food Animal Practice*^{1,2}; this article focuses on the developments that have occurred over the past decade.

INNATE IMMUNOLOGY OF BOVINE RESPIRATORY DISEASE

Pattern Recognition Receptors

The innate immune system utilizes an array of soluble, surface-bound and intracellular receptors to detect the presence of invading pathogens. These receptors, termed *pattern recognition receptors (PRRs)*, recognize conserved molecular patterns, known as *pathogen-associated molecular patterns (PAMPs)*. Common PAMPs include peptidoglycan and lipoteichoic acids from gram-positive bacteria, lipopolysaccharide (LPS) from gram-negative bacteria, CpG-rich DNA, and single-stranded and double-stranded RNA. Together, the cells that comprise the bovine respiratory tract express a full arsenal of surface-bound and intracellular PRRs, including Toll-like receptors (TLRs), NOD-like receptors, and RNA helicases, such as RIG-I and MDA-5. All pathogens of the BRD complex produce some type of PAMP that activate the innate immune system.

Infection induces up-regulation of many PRRs, preparing an animal to mount a robust response to the insult. In vitro infection of bovine bronchial epithelial cells by bovine herpesvirus (BHV)-1 or *Mannheimia haemolytica* results in up-regulation of TLR2,³ a PRR generally involved in the recognition of gram-positive bacteria. In vivo infection with BHV-1 induces up-regulation of TLR3, TLR7, TLR8, and TLR9 in the nasal mucosa, tracheal epithelium, and lung.⁴ A transcriptome analysis of the bronchial lymph nodes of calves singly infected with BRD pathogens revealed a global up-regulation of many PRR-associated genes, although there was some specificity in the response to particular pathogens.⁵ Although *M haemolytica* infection induced selective up-regulation of TLR1 and TLR6, infection with BHV-1, bovine respiratory syncytial virus (BRSV) or bovine viral diarrhea virus (BVDV) induced more pronounced up-regulation of TLR2 and TLR4.⁵ The biological significance of these differences is not immediately clear but warrants further investigation. In an in vitro coinfection model, exposure of alveolar type 2 epithelial cells to *Histophilus somni* induced activation of the type I interferon (IFN) response, which subsequently protected the cells from BRSV infection. Thus, global activation in innate immune sensors may be an

important defense strategy. Other reports, however, have shown that this response may not always be beneficial. Acute stress, such as that caused by abrupt weaning and shipping, results in increased expression of TLR4, CD14, and the IFN-responsive gene 2,5-OAS by circulating peripheral blood mononuclear cells (PBMCs).⁶ Although this increase resulted in an enhanced capacity by the cells to respond to LPS (also known as endotoxin) stimulation, a significant positive association was found between PRR expression and risk of mortality from a subsequent BHV and *M haemolytica* challenge.⁶

Airway and Lung Epithelia and Resistance to Bovine Respiratory Disease

Although not often included under the purview of the immune system, airway epithelial cells play a critical role in the first line of defense against infection. The mucociliary escalator is responsible for the removal of inhaled particles, including invading pathogens. One study of healthy animals showed that greater than 90% of aerosolized *M haemolytica* could be eliminated from the lung within 4 hours of administration, primarily due to ciliary action.⁷ Viral pathogens, however, such as BRSV, BHV, and parainfluenza virus (PIV), cause ciliary dysfunction and necrosis,^{1,8} which can lead to significant delays in the clearance of inhaled particles.⁹ Thus, interference with normal ciliary function may be 1 explanation by which primary viral infections predispose cattle to secondary bacterial pneumonia.

Bovine airway epithelial cells express many PRRs, and are responsive to common TLR agonists, such as LPS, which signals through TLR4, and Pam3CSK4, which activates TLR2.^{10,11} Epithelial cells of the respiratory tract produce several antimicrobial molecules, including lactoferrin, tracheal antimicrobial peptide (TAP), lingual antimicrobial peptide (LAP), and bovine myeloid antimicrobial peptide (BMAP-28), which accumulate in the mucus and periciliary layers of the air-surface interface. Stimulation with LPS or Pam3CSK induces secretion of LAP, TAP, and lactoferrin, preparing the tissues to ward off invading bacterial pathogens.^{11,12} TAP has bactericidal activity against *M haemolytica*, *H somni*, and *Pasteurella multocida*,¹³ whereas BMAP-28 can kill *P multocida* in vitro.¹⁴ Viral infections can interfere with the production of antimicrobial peptides by epithelial cells. For example, prior infection with BVDV inhibits pathogen-induced expression of both LAP and lactoferrin by tracheal epithelial cells.¹²

Airway epithelial cells also can play a role in the antiviral immune response. In vivo infection with BHV-1 results in rapid activation of the type I IFN response in the trachea, including secretion of type I and type II IFNs and induction of the interferon-stimulated genes *Mx1*, *OAS*, and *BST-2*.¹⁵ BHV, and many other viruses of the BRD complex, including BVDV, BRSV, and PIV, however, have mechanisms in place to actively suppress the host IFN response.^{16–19} In 1 report, coinfection of bovine epithelial cells with BVDV inhibited type I IFN production, enabling significantly increased replication of BRSV in the same cell cultures,¹⁹ suggesting a synergistic interaction between the 2 viruses.

Perhaps the most critical result of an insult to the airway epithelia is the engagement of the effector arm of the innate immune system. In vitro, invasion of bovine bronchial epithelial cells by *M haemolytica*, or infection with BHV-1, induces rapid secretion of the proinflammatory cytokines interleukin (IL)-6, tumor necrosis factor (TNF)- α , and IL-8, leading to the recruitment and activation of innate immune effector cells, such as neutrophils.^{3,20} Coinfection of bronchial epithelial cells with both BHV-1 and *M haemolytica* has been shown to exacerbate proinflammatory responses by bovine epithelial cells, resulting in greater cytokine expression by dually infected cells compared with either single pathogen alone.^{3,20} Similar results also have been shown after coinfection of bovine bronchial epithelial cells with BRSV and *P multocida*.²¹ Proinflammatory

cytokines, however, are not the only factors that can contribute to lung damage. In vitro infection of bovine alveolar type 2 cells with BRSV and *H somni* results in significant up-regulation of matrix metalloproteinases 1 and 3, enzymes that break down collagen, thus enhancing the invasion of *H somni* across the alveolar barrier.²²

Airway epithelial cells also may play a role in regulating the inflammatory response in the respiratory tract. Annexin A1 and annexin A2 are anti-inflammatory proteins produced by airway epithelial cells that regulate neutrophil recruitment and activation, similar to glucocorticoids. Increased concentrations of annexin A1 and annexin A2 in the bronchoalveolar lavage (BAL) fluid prior to challenge have been shown to correlate with improved resistance to the later development of BRD.²³

Effector Cells of the Innate Immune System

Neutrophils

Neutrophils are among the first cell type to be recruited to the site of infection, migrating from the blood in response to proinflammatory cytokines and chemotactic factors, such as IL-8. Neutrophils are highly phagocytic cells that play an important role in protecting the host against extracellular bacterial infections. It is clear, however, that neutrophils also play a major role in lung tissue destruction during BRD. Depletion of neutrophils,²⁴ or inhibition of neutrophil infiltration to the respiratory tract,²⁵ prior to *M haemolytica* infection results in a significant decrease in inflammatory cytokine and lung pathology.

Neutrophil extracellular traps (NETs) have emerged as 1 important factor contributing to BRD pathogenesis. Neutrophils have the capacity to undergo NETosis, a form of cell death in which neutrophils release their nuclear DNA and associated proteins into the extracellular environment. *M haemolytica*²⁶, *Mycoplasma bovis*,²⁷ and *H somni*²⁸ cause neutrophil NET formation in vitro, and evidence of NETs has been observed in the lungs of calves infected with both *M haemolytica*²⁶ and *H somni*.²⁸ There is some debate as to whether NETs are an active form of host defense or simply an artifact of neutrophil cell death. In vitro, NETs can kill *M haemolytica* and *H somni*, suggesting some active role in immunity, but the relevance of this antimicrobial activity is difficult to investigate in vivo in the morbid animal. *Mycoplasma bovis* is not susceptible to NET-mediated killing in vitro,²⁷ potentially due to its ability to release nucleases and degrade the extracellular DNA.²⁹ Citrullinated histone 3, an indicator of NETs, is increased in the BAL fluid of calves with severe BRSV infection,³⁰ and NETs have been observed microscopically in the lungs of calves with BRSV infection,³¹ demonstrating that NETosis is not specific to bacterial invasion. In calves with BRSV, NETs form dense networks, entrapping mucin and cells, leading to airway occlusion.³¹ Consistent with the idea the NETs play a pathogenic role, aerosol administration of dornase alfa, a synthetic form of DNase I that can degrade NETs, considerably reduced airway obstruction and improved lung pathology in a small group of calves infected with BRSV.³²

Antigen-presenting cells: monocytes, macrophages and dendritic cells

Antigen-presenting cells (APCs), including monocytes, macrophages, and dendritic cells, are critical in bridging the innate and adaptive immune systems. Dendritic cells in particular are essential to the induction of an effective T-cell and B-cell response. Monocytes and macrophages also fulfill the role of an APC but are similarly active in phagocytosis of dead and dying cells; killing of extracellular pathogens and inflammatory cytokine production.

BVDV infection is a major predisposing factor for BRD due to its known immunosuppressive effects on cells of both the innate and adaptive immune systems. In alveolar

macrophages, noncytopathic BVDV infection suppresses proinflammatory cytokine secretion and reduces phagocytic activity. In vitro infection of monocyte-derived macrophages with both cytopathic and noncytopathic strains of BVDV suppresses responsiveness to ligands for TLR2, TLR3, and TLR4 but does not alter signaling through TLR7.³³ Similarly, in vivo BVDV infection also modulates the capacity of monocytes and macrophages to respond via TLR4.³⁴

Like BVDV, several other viruses have an impact on APC activation and function. PIV infection suppresses macrophage phagocytosis and inhibits oxidative burst.^{35,36} PIV-infected macrophages, however, are hyperresponsive to LPS stimulation, producing significantly increased quantities of TNF- α .³⁷ BRSV infection also inhibits alveolar macrophage phagocytosis but does not appear to impair the oxidative burst response.³⁸ In vitro BRSV infection of ovine alveolar macrophages induces only low-level proinflammatory cytokine expression.³⁹ In vivo infection of lambs also results in only limited activation of lung-resident dendritic cells, with no significant changes in major histocompatibility complex (MHC) class I or the costimulatory molecules CD80 or CD86. Instead, both lung dendritic cells and alveolar macrophages significantly up-regulate gene expression of IL-4 and IL-10.³⁹ In vivo BHV-1 infection induces recruitment of interstitial and alveolar macrophages to the lungs, and induces production of proinflammatory cytokines, such as TNF α , IL-1 α , and induced nitric oxide synthase (iNOS).⁴⁰ Calves coinfecting with BVDV and BHV-1 show greater numbers of infiltrating macrophages than animals that are singly infected but reduced production of iNOS and the proinflammatory mediators TNF- α and IL-1 α .⁴⁰

ADAPTIVE IMMUNOLOGY OF BOVINE RESPIRATORY DISEASE

The development of an adaptive immune response is critical for control and clearance of respiratory pathogens. After infection, cattle mount antibody (Ab) and antigen-specific T-cell responses; however, pathogens frequently evade these immune responses by using multiple strategies. Many of these immune evasion strategies have been covered in reviews of the specific pathogens.^{41–44}

B cells and antibody responses

B-cell surface immunoglobulins recognize pathogen epitopes. After antigen recognition and additional downstream signals, B cells terminally differentiate into antibody (Ab)-secreting plasma cells. The Ab secreted play important roles in defending the host from infection with respiratory pathogens. Those roles include neutralizing Ab (nAb), complement activation, Fc Receptor-mediated phagocytosis, and Ab-dependent cellular cytotoxicity. On the other hand, specific Ab against respiratory pathogens and the resultant immune complexes may contribute to BRD pathogenesis.

The protective antigens of Pasteurellaceae family members have not been fully elucidated. There are studies, however, that have shown that Ab that neutralize toxins or Ab against LPS, outer membrane proteins, or secreted antigens can be protective.⁴⁵ For example, Ab to *M haemolytica* serotype 1 outer membrane lipoprotein PlpE cross-protects against other serotypes and these Ab promote complement-mediated bacterial killing.⁴⁶ Antibodies against the surface exposed outer membrane lipoprotein Gs60 can be protective and have been suggested as especially important in protection against *M haemolytica* when nAb titers to the *M haemolytica* leukotoxin are low.⁴⁷ Other Pasteurellaceae, including *P multocida* and *H somni*, have Gs60 homologues,⁴⁷ and these also may be targets of protective Ab. In addition, vaccination of calves with sialoglycoprotease enhances protection against experimental disease due

to *M haemolytica*.⁴⁸ Fewer studies have been conducted to identify antigens associated with protection from *P multocida* challenge. As was the case for *M haemolytica*, however, Ab generated against outer membrane proteins of *P multocida* have been shown to be an important component of host defense. Intranasal treatment with *P multocida* outer membrane protein H induced both serum IgG and secretory IgA levels that protected calves from experimental challenge with *P multocida*.⁴⁹ Although studies have yet to be conducted in cattle, a recombinant outer membrane lipoprotein B from *P multocida* serotype A strain was shown to induce serum Ab in mice with significant bacterial killing activity.⁵⁰ Regarding *H somni* immunity, antibodies to a 40-kDa outer membrane protein (OMP) have been found protective, whereas those to a 78-kDa OMP are not.⁴¹ Furthermore, 40-kDa OMP IgG1 antibodies protected less effectively than IgG2. In calves vaccinated with a commercial *H somni* vaccine and then experimentally challenged, IgG2 levels were shown to inversely correlate with disease severity in response to experimental infection.⁵¹

Seroconversion is detectable 14 days to 28 days after experimental respiratory infection with *Mycoplasma bovis*.⁵² The primary serum Ab detected in calves is IgG1,⁵³ which corresponds with a predominance of IgG1 plasma cells in the lungs of calves experimentally infected with *Mycoplasma bovis*.⁴³ In cattle, IgG1 is known to be a poorer opsonin for phagocytosis and killing than IgG2, and this may be 1 strategy which *Mycoplasma bovis* uses for immune evasion.⁴³ Moreover, new antigenically distinct variants of *Mycoplasma bovis* variable surface proteins⁵⁴ arise in response to Ab that target these immunodominant surface lipoproteins which further facilitates evasion of host defenses, until adaptive immunity can again respond.

nAb are critical in the response to bovine respiratory viral pathogens. Viral glycoproteins (g) are targets of these Ab against BHV-1, including gB, gC, gD, and gH. Among these, gD has been shown to elicit especially strong nAb titers compared with gC or tegument protein VP8 when delivered via DNA vaccination.⁵⁵ Thus, researchers have sought to identify epitopes on gD important for virus neutralization, several of which have been defined, including recently described highly conserved, neutralizing epitopes within the amino and carboxy termini of BHV-1 gD.^{56,57} Experimental evidence indicates that BVDV envelope E2 is not only the major immunodominant glycoprotein but also the most variable for BVDV isolates. nAb induced against E2 after natural infection or after vaccination is considered protective against BVDV.⁵⁸ To provide information for future vaccines, investigators have mapped neutralizing epitopes and characterized neutralizing monoclonal Ab that bind to E2.⁵⁸ Protective Ab responses to BRSV predominately target the F, G, and NP proteins, although calves mount responses to several antigens. Specific Ab can be detected in nasal secretions by day 8 postinfection. Time to detection of BRSV-specific serum IgG1 and IgG2 differs, with IgG1 observed at approximately day 13, whereas IgG2 is not detected until 1 month to 3 months after infection.⁵⁹ In either case, the IgG subclass responses wane rapidly. Important in protection from BRSV are nAb against F and G. Neutralizing epitopes have been defined for the prefusion and postfusion F proteins, with the most potent targeting the prefusion protein.⁶⁰ In addition, the conserved central core domain of G is an important target of broadly nAb.

Gamma delta T cells

Gamma delta ($\gamma\delta$) T cells play an early role in the host immune response and have functions related to both innate and adaptive immunity. High levels of $\gamma\delta$ T cells are found in the peripheral blood of cattle, especially in young calves, where they can

comprise up to 60% of lymphocyte pool.⁶¹ These cells are found in large proportions at mucosal sites, including the respiratory tract, where they serve as part of a first line of defense against invading pathogens.

Relatively few studies have examined $\gamma\delta$ T cell responses to bovine respiratory bacterial pathogens, which is somewhat remarkable given their relative abundance in calves. The authors have shown that *M haemolytica* can exacerbate the expression of the inflammatory cytokine IL-17 induced by BRSV infection and that $\gamma\delta$ T cells are a primary producer of IL-17 using an in vitro model system.⁶² No enhancement of IL-17 was seen, however, when PBMCs were cocultured with BRSV and *P multocida*. After challenge of previously immunized calves with *P multocida*, an increase in CD5, CD8, and MHC class II expression was found on activated $\gamma\delta$ T cells in BAL samples.⁶³ After *Mycoplasma bovis* lung infection in calves, $\gamma\delta$ T cells isolated from peripheral blood and restimulated with heat-inactivated *Mycoplasma bovis* antigen exhibited higher levels of the activation marker CD25.⁵³ Activated $\gamma\delta$ T cells could be 1 source of the intracellular IFN- γ that was measured from in vitro activated PBMCs in that study.

In response to BHV-1 modified live vaccination and subsequent challenge in calves, increased peripheral blood $\gamma\delta$ T cells with an activated phenotype were observed.⁶⁴ In response to intrabronchial challenge with BVDV1, expansion of $\gamma\delta$ T cells in BAL fluid of calves has been reported.⁶⁵ The authors' group has found expression of the surface molecule WC1.1 correlates with increased $\gamma\delta$ T cell chemokine elaboration during BRSV infection in calves, suggesting that these cells may contribute to recruitment of inflammatory cells.⁶⁶ Earlier work of others had shown that depletion of WC1.1-expressing cells did not have an impact on the clinical course of disease in BRSV-infected calves but rather resulted in significantly increased local IgM and IgA responses.⁶⁷

Alpha/beta T cells

As discussed previously for $\gamma\delta$ T cells, there has been limited investigation of bovine alpha/beta ($\alpha\beta$) T cells after infection with members of the Pasteurellaceae family. Experimental infection of naïve calves with *P multocida* resulted in a significant increase in the percentage of activated CD8⁺ T cells in BAL that express MHC II compared with control-naïve calves; however, no significant differences in these cells were seen between immunized control and immunized challenged groups of calves.⁶³ In addition, increased bronchus-associated lymphoid tissue was noted in lung tissue and an increase in the number of MHC class II-expressing CD4⁺ T cells was observed in draining lymph nodes after challenge.

Cellular immune responses have been measured using PBMCs isolated from calves after experimental lung infection with *Mycoplasma bovis*.⁵³ Heat-killed *M bovis* activated CD4⁺ and CD8⁺ peripheral blood subpopulations in vitro as measured by flow cytometric analyses. Moreover, as equal percentages of simulated cells produced IFN- γ and IL-4 cytokine responses,⁵³ indicative of a mixed systemic cytokine response. Local immune responses in lung tissue were evaluated after challenge with *Mycoplasma bovis*; however, no statistical differences in numbers of CD4⁺ or CD8⁺ T-cell subsets were noted.⁶⁸

Although nAb are critical in protection against bovine respiratory viruses, there is an important role for cellular immunity involving both CD4⁺ and CD8⁺ T cells. CD4⁺ T cells are considered essential for clearance of BHV-1, with recognition of glycoproteins gB, gC, gD, and VP8 by these immune cells.⁴⁴ Defining antigenic regions within these major glycoproteins recognized by CD4⁺ T cells is important for novel vaccines strategies for BHV-1, and, in this regard, CD4⁺ T cells epitopes have been mapped on gB⁶⁹ and gD.⁷⁰ Similarly, gC and gD have been shown to be targets of cytotoxic CD8⁺

T cells. Importantly, CD8⁺ T cells may play a role in control of re-establishment of active infection from latency.⁴⁴ CD4⁺ and CD8⁺ $\alpha\beta$ T cells are critical in the response to BRSV. The F and G proteins are the major class II-restricted targets in cattle, with multiple antigenic regions described for the F protein of BRSV. CD8⁺ T cells are critical for clearance of BRSV, with M2, F, N, and G targets described.⁷¹ Increased CD8⁺ T-cell infiltration in several tissues has been seen during BRSV infection, with cytotoxic CD8⁺ T-cell activity peaking at 7 days to 10 days postinfection.⁷² BVDV infections generate peripheral CD4 T cells that can recognize structural and nonstructural epitopes, including those on E2 and NS3 as dominant MHC class II epitopes.⁷³ Increased numbers of activated CD4 and CD8 T cells have been noted in BAL in response to primary and secondary cytopathic BVDV intrabronchial challenge.⁶⁵

FACTORS THAT HAVE AN IMPACT ON IMMUNITY AND SUSCEPTIBILITY TO BOVINE RESPIRATORY DISEASE

Stress and Immunity

Multiple studies have postulated a link between stress and incidence and severity of respiratory infections. Stress often is a broadly used term to describe adverse circumstances or an alteration induced in an individual as a result of those circumstances. In cases of BRD, the stresses may be categorized generally as psychological, physiologic, and/or nutritional. Thus, stresses in calves can include those associated with weaning, veterinary procedures, transport, comingling, crowding, and dietary changes, among other factors. There is conflicting evidence in the literature on the impact of some of these factors in inducing altered serum stress markers (eg, cortisol levels) and how these may influence bacterial or viral infections or viral-bacterial coinfections associated with BRD.⁷⁴ There seems to be strong evidence, however, that weaning and transportation are stressors that contribute to severity of BRD.⁷⁵

Genetics of Disease Resistance

Over the past decades, it has become clear that genetics play a significant role in determining resistance and susceptibility to a wide variety of disease conditions in humans and livestock. In cases of BRD, cattle of the same age and housed under the same conditions vary greatly in their tendency to develop disease, and the severity of the resultant clinical signs. This individual variability strongly suggests some degree of genetic control. Genetic regulation of disease susceptibility was reviewed in a recent edition of *Veterinary Clinics of North America: Food Animal Practice*.⁷⁶ This section provides only a brief summary of recent findings related to BRD and the genetic component of disease susceptibility.

Quantitative-trait locus mapping has revealed some regions linked to BRD susceptibility. Two single-nucleotide polymorphisms (SNPs) on BTA20, identified as the *ANKRA2* gene and the *CD180* gene, were shown to associate with susceptibility to BRD.⁷⁷ *ANKRA2* plays a role in transcription of the MHC class II genes, whereas *CD180* is a gene in the TLR family and is important for B-cell responsiveness to LPS. Polymorphisms have been identified in other innate bovine PRRs, including TLR, RIG-I, NOD2, and mannose-binding lectin.⁷⁸ Although there currently is little evidence to directly link these SNPs to BRD susceptibility, 1 study has suggested that polymorphisms in TLR4 and TLR8 contribute to increased responsiveness to BRSV vaccination.⁷⁸ In a recent study, gene set enrichment analysis identified glucose as the most important upstream regulator of BRD susceptibility in dairy cattle. In the same study, TNF was identified as the most significant upstream regulator

in beef cattle, influencing 64 downstream genes that were associated with the immune response.⁷⁹ Comparisons between the beef and dairy populations in this studied identified 6 BRD-associated SNPs that were shared between the groups, located in the genes *ADIPOQ*, *HTR2A*, *MIF*, *PDE6G*, *PRDX3*, and *SNCA*.⁷⁹ All 6 genes are known to be involved in down-regulating TNF production and in the metabolism of reactive oxygen species.⁷⁹ It is expected that the next decade will bring continued advancements in understanding of the genetic components of this pervasive syndrome.

NOVEL INTERVENTION STRATEGIES FOR USE AGAINST BOVINE RESPIRATORY DISEASE

Vaccination and effective management strategies are the foundation of BRD prevention. Metaphylactic use of antibiotics generally is effective against BRD and is an essential tool for controlling outbreaks. There are ongoing concerns, however, regarding the development of antimicrobial resistance, and significant research efforts currently are aimed at designing new approaches for BRD prevention. Vaccines are the focus of another article in this edition. Therefore, this section is focused on a few promising alternative intervention strategies, which are being developed to reduce the impact of BRD in the dairy and feedlot.

Antimicrobial Peptides as Alternatives to Antibiotics for Bovine Respiratory Disease Control

The bovine innate immune system produces several antimicrobial peptides and several have been explored for their use as therapeutic alternatives to antibiotics. NK-lysin is an antimicrobial peptide that has been described in the granules of cytotoxic T cells and NK cells in humans, pigs, and cattle. Although humans and pigs have only a single NK-lysin gene, cattle have 4 functional NK-lysin genes, *NK1*, *NK2A*, *NK2B*, and *NK2C*.^{80,81} NK-lysin gene expression is up-regulated in the lungs of animals infected with *Mycoplasma bovis*, *M haemolytica*, *P multocida*, BVDV, BRSV, and BHV-1.⁸⁰ In vitro, NK-lysin has antimicrobial activities against *M haemolytica*, *P multocida*, and *H somni*, although susceptibility to the 4 individual NK-lysin peptides differs between species.^{80,82} *Mycoplasma bovis* is susceptible only to NK2A and NK2C peptides, and these are effective only at relatively high concentrations,⁸³ suggesting that NK-lysin may not be an ideal therapeutic candidate for this organism.

TAP is a β -defensin produced by airway epithelial cells. TAP gene expression is induced in bovine epithelial cells in response to TLR stimulation or IL-17A^{10,11} and is up-regulated in the lungs of calves with *M haemolytica* pneumonia.⁸⁴ In vitro, TAP has potent bactericidal activity against *M haemolytica*, *P multocida*, and *H somni*, although *Mycoplasma bovis* is resistant to TAP treatment.¹³ In a recent study, TAP was administered therapeutically, via aerosol or intranasal administration, to neonatal calves that had been challenged with *M haemolytica*.⁸⁵ Unfortunately, TAP treatment had little effect on *M haemolytica* disease. Further investigation revealed that physiologic concentrations of sodium chloride, such as the concentrations present in nasal secretions or serum, inhibited TAP-mediated bactericidal activity in vitro.⁸⁵

Innate Immunomodulation as a Novel Strategy for Controlling Bovine Respiratory Disease

Although vaccine development continues to be an active area of research, the past decade has seen increasing interest in strategies to influence the innate immune system. Immunology dogma has long taught that the innate immune system is

nonspecific and does not improve with repeated exposure. It has become apparent, however, that, in fact, the innate immune system can be primed, or trained, by exposure to certain organisms or molecules, that results in an enhanced state of responsiveness to secondary stimuli. This enhanced state of responsiveness, termed trained immunity, is induced primarily in myeloid cells (monocytes and macrophages) and NK cells⁸⁶ and results in superior cytokine expression and ultimately, enhanced capacity to prevent infection. Mechanistic studies have demonstrated that trained immunity is independent of adaptive immunity and is caused by epigenetic reprogramming and alterations in basal intracellular metabolic pathways, which result in changes in gene expression and cell physiology leading to increased innate immune cells' capacity to respond to stimulation.⁸⁶ The idea of enhancing an animal's innate state of disease resistance is appealing, particularly during well-defined periods of stress, such as during weaning and shipping. Several recent therapies have emerged with potential to train or enhance the innate immune system during times of stress. One such DNA-based immunostimulant, marketed as the commercial product Zelnote (Bayer Animal Health, Shawnee Mission, KS, USA), has been shown to reduce lung pathology scores in cattle experimentally challenged with *M haemolytica*⁸⁷ and significantly reduce mortality in high-risk cattle after feedlot placement.^{88,89} Although the product's exact mechanisms of action is not well defined, it may be stimulating the immune system via the innate cytosolic DNA sensing cGAS-STING pathway.⁹⁰ Another immunomodulatory product, marketed as Amplimune (Novavive, Inc, located in Napanee, Ontario, Canada), is a mycobacterium cell wall fraction derived from the nonpathogenic *Mycobacterium phlei*. Amplimune nonspecifically activates the innate immune system and has been successfully applied for prevention of K99 *Escherichia coli* in preweaned calves. A promising study revealed, however, that Amiplimune had beneficial effects in reducing incidence and mortality associated with BRD in newly received, light-weight beef calves.⁹¹

SUMMARY

The innate and adaptive immune systems are well equipped to protect the lung from pathogen invasion. BRD is a complex syndrome, however, caused by multiple factors, including environmental and management-related stressors and viral and bacterial pathogens. In combination, these factors overwhelm and dysregulate host immunity and lead to disease. Although vaccination and antimicrobial therapy remain the primary methods for controlling BRD, several novel strategies currently are being investigated as alternatives, including innate immunomodulation and selection of genetically resistant stock.

DISCLOSURE

Research was supported by funds from the Agriculture and Food Research Initiative Competitive Grant No. 2018-06904 from the USDA National Institute of Food and Agriculture to JLM; and appropriated funds from the USDA Agricultural Research Service CRIS projects 5030-32000-116-00D and 5030-32000-117-00D to RES.

REFERENCES

1. Ackermann MR, Derscheid R, Roth JA. Innate immunology of bovine respiratory disease. *Vet Clin North Am Food Anim Pract* 2010;26:215–28.
2. Ellis JA. The immunology of the bovine respiratory disease complex. *Vet Clin North Am Food Anim Pract* 2001;17:535–50, vi-vii.

3. N'jai AU, Rivera J, Atapattu DN, et al. Gene expression profiling of bovine bronchial epithelial cells exposed in vitro to bovine herpesvirus 1 and *Mannheimia haemolytica*. *Vet Immunol Immunopathol* 2013;155:182–9.
4. Marin MS, Quintana S, Faverin C, et al. Toll-like receptor activation and expression in bovine alpha-herpesvirus infections. *Res Vet Sci* 2014;96:196–203.
5. Tizioto PC, Kim J, Seabury CM, et al. Immunological response to single pathogen challenge with agents of the bovine respiratory disease complex: an RNA-sequence analysis of the bronchial lymph node transcriptome. *PLoS One* 2015; 10:e0131459.
6. Hodgson PD, Aich P, Stookey J, et al. Stress significantly increases mortality following a secondary bacterial respiratory infection. *Vet Res* 2012;43:21.
7. Lopez A, Maxie MG, Savan M, et al. The pulmonary clearance of *Pasteurella haemolytica* in calves infected with bovine virus diarrhea or *Mycoplasma bovis*. *Can J Comp Med* 1982;46:302–6.
8. Caswell JL. Failure of respiratory defenses in the pathogenesis of bacterial pneumonia of cattle. *Vet Pathol* 2014;51:393–409.
9. Gershwin LJ, Gunther RA, Hornof WJ, et al. Effect of infection with bovine respiratory syncytial virus on pulmonary clearance of an inhaled antigen in calves. *Am J Vet Res* 2008;69:416–22.
10. Taha-Abdelaziz K, Wyer L, Berghuis L, et al. Regulation of tracheal antimicrobial peptide gene expression in airway epithelial cells of cattle. *Vet Res* 2016;47:44.
11. Berghuis L, Abdelaziz KT, Bierworth J, et al. Comparison of innate immune agonists for induction of tracheal antimicrobial peptide gene expression in tracheal epithelial cells of cattle. *Vet Res* 2014;45:105.
12. Al-Haddawi M, Mitchell GB, Clark ME, et al. Impairment of innate immune responses of airway epithelium by infection with bovine viral diarrhea virus. *Vet Immunol Immunopathol* 2007;116:153–62.
13. Taha-Abdelaziz K, Perez-Casal J, Schott C, et al. Bactericidal activity of tracheal antimicrobial peptide against respiratory pathogens of cattle. *Vet Immunol Immunopathol* 2013;152:289–94.
14. Brogden KA, Nordholm G, Ackermann M. Antimicrobial activity of cathelicidins BMAP28, SMAP28, SMAP29, and PMAP23 against *Pasteurella multocida* is more broad-spectrum than host species specific. *Vet Microbiol* 2007;119:76–81.
15. Osman R, Gonzalez-Cano P, Brownlie R, et al. Induction of interferon and interferon-induced antiviral effector genes following a primary bovine herpesvirus-1 (BHV-1) respiratory infection. *J Gen Virol* 2017;98:1831–42.
16. Bossert B, Marozin S, Conzelmann KK. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. *J Virol* 2003;77:8661–8.
17. Eberle KC, McGill JL, Reinhardt TA, et al. Parainfluenza virus 3 blocks antiviral mediators downstream of the interferon lambda receptor by modulating stat1 phosphorylation. *J Virol* 2015;90:2948–58.
18. Palomares RA, Walz HG, Brock KV. Expression of type I interferon-induced antiviral state and pro-apoptosis markers during experimental infection with low or high virulence bovine viral diarrhea virus in beef calves. *Virus Res* 2013;173: 260–9.
19. Alkheraif AA, Topliff CL, Reddy J, et al. Type 2 BVDV Npro suppresses IFN-1 pathway signaling in bovine cells and augments BRSV replication. *Virology* 2017;507:123–34.

20. Rivera-Rivas JJ, Kisiela D, Czuprynski CJ. Bovine herpesvirus type 1 infection of bovine bronchial epithelial cells increases neutrophil adhesion and activation. *Vet Immunol Immunopathol* 2009;131:167–76.
21. Sudaryatma PE, Nakamura K, Mekata H, et al. Bovine respiratory syncytial virus infection enhances *Pasteurella multocida* adherence on respiratory epithelial cells. *Vet Microbiol* 2018;220:33–8.
22. Agnes JT, Zekarias B, Shao M, et al. Bovine respiratory syncytial virus and *Histophilus somni* interaction at the alveolar barrier. *Infect Immun* 2013;81:2592–7.
23. Senthilkumaran C, Clark ME, Abdelaziz K, et al. Increased annexin A1 and A2 levels in bronchoalveolar lavage fluid are associated with resistance to respiratory disease in beef calves. *Vet Res* 2013;44:24.
24. Breider MA, Walker RD, Hopkins FM, et al. Pulmonary lesions induced by *Pasteurella haemolytica* in neutrophil sufficient and neutrophil deficient calves. *Can J Vet Res* 1988;52:205–9.
25. Radi ZA, Caverly JM, Dixon RA, et al. Effects of the synthetic selectin inhibitor TBC1269 on tissue damage during acute Mannheimia haemolytica-induced pneumonia in neonatal calves. *Am J Vet Res* 2001;62:17–22.
26. Aulik NA, Hellenbrand KM, Klos H, et al. Mannheimia haemolytica and its leukotoxin cause neutrophil extracellular trap formation by bovine neutrophils. *Infect Immun* 2010;78:4454–66.
27. Gondaira S, Higuchi H, Nishi K, et al. Mycoplasma bovis escapes bovine neutrophil extracellular traps. *Vet Microbiol* 2017;199:68–73.
28. Hellenbrand KM, Forsythe KM, Rivera-Rivas JJ, et al. *Histophilus somni* causes extracellular trap formation by bovine neutrophils and macrophages. *Microb Pathog* 2013;54:67–75.
29. Mitiku F, Hartley CA, Sansom FM, et al. The major membrane nuclease MnuA degrades neutrophil extracellular traps induced by Mycoplasma bovis. *Vet Microbiol* 2018;218:13–9.
30. Hagglund S, Blodorn K, Naslund K, et al. Proteome analysis of bronchoalveolar lavage from calves infected with bovine respiratory syncytial virus-Insights in pathogenesis and perspectives for new treatments. *PLoS One* 2017;12:e0186594.
31. Cortjens B, de Boer OJ, de Jong R, et al. Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease. *J Pathol* 2016;238:401–11.
32. Cortjens B, de Jong R, Bonsing JG, et al. Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection. *Thorax* 2018;73:578–80.
33. Schaut RG, Ridpath JF, Sacco RE. Bovine viral diarrhea virus type 2 impairs macrophage responsiveness to toll-like receptor ligation with the exception of toll-like receptor 7. *PLoS One* 2016;11:e0159491.
34. Schaut RG, McGill JL, Neill JD, et al. Bovine viral diarrhea virus type 2 in vivo infection modulates TLR4 responsiveness in differentiated myeloid cells which is associated with decreased MyD88 expression. *Virus Res* 2015;208:44–55.
35. Liggitt D, Huston L, Silflow R, et al. Impaired function of bovine alveolar macrophages infected with parainfluenza-3 virus. *Am J Vet Res* 1985;46:1740–4.
36. Slauson DO, Lay JC, Castleman WL, et al. Alveolar macrophage phagocytic kinetics following pulmonary parainfluenza-3 virus infection. *J Leukoc Biol* 1987;41:412–20.

37. Bienhoff SE, Allen GK, Berg JN. Release of tumor necrosis factor- α from bovine alveolar macrophages stimulated with bovine respiratory viruses and bacterial endotoxins. *Vet Immunol Immunopathol* 1992;30:341–57.
38. Trigo E, Liggitt HD, Evermann JF, et al. Effect of in vitro inoculation of bovine respiratory syncytial virus on bovine pulmonary alveolar macrophage function. *Am J Vet Res* 1985;46:1098–103.
39. Fach SJ, Olivier A, Gallup JM, et al. Differential expression of cytokine transcripts in neonatal and adult ovine alveolar macrophages in response to respiratory syncytial virus or toll-like receptor ligation. *Vet Immunol Immunopathol* 2010;136:55–64.
40. Risalde MA, Molina V, Sánchez-Cordón PJ, et al. Pathogenic mechanisms implicated in the intravascular coagulation in the lungs of BVDV-infected calves challenged with BHV-1. *Vet Res* 2013;44:20.
41. Corbeil LB. Host immune response to *Histophilus somni*. *Curr Top Microbiol Immunol* 2016;396:109–29.
42. Srikumaran S, Kelling CL, Ambagala A. Immune evasion by pathogens of bovine respiratory disease complex. *Anim Health Res Rev* 2007;8:215–29.
43. Maunsell FP, Chase C. *Mycoplasma bovis*: interactions with the immune system and failure to generate an effective immune response. *Vet Clin North Am Food Anim Pract* 2019;35:471–83.
44. Levings RL, Roth JA. Immunity to bovine herpesvirus 1: II. Adaptive immunity and vaccinology. *Anim Health Res Rev* 2013;14:103–23.
45. Confer AW, Ayalew S. *Mannheimia haemolytica* in bovine respiratory disease: immunogens, potential immunogens, and vaccines. *Anim Health Res Rev* 2018;19:79–99.
46. Ayalew S, Blackwood ER, Confer AW. Sequence diversity of the immunogenic outer membrane lipoprotein PlpE from *Mannheimia haemolytica* serotypes 1, 2, and 6. *Vet Microbiol* 2006;114:260–8.
47. Orouji S, Hodgins DC, Lo RY, et al. Serum IgG response in calves to the putative pneumonic virulence factor Gs60 of *Mannheimia haemolytica* A1. *Can J Vet Res* 2012;76:292–300.
48. Shewen PE, Lee CW, Perets A, et al. Efficacy of recombinant sialoglycoprotease in protection of cattle against pneumonic challenge with *Mannheimia* (*Pasteurella*) *haemolytica* A1. *Vaccine* 2003;21:1901–6.
49. Muangthai K, Tankaew P, Varinrak T, et al. Intranasal immunization with a recombinant outer membrane protein H based *Haemorrhagic septicemia* vaccine in dairy calves. *J Vet Med Sci* 2018;80:68–76.
50. Wei X, Wang Y, Luo R, et al. Identification and characterization of a protective antigen, PlpB of bovine *Pasteurella multocida* strain LZ-PM. *Dev Comp Immunol* 2017;71:1–7.
51. Berghaus LJ, Corbeil LB, Berghaus RD, et al. Effects of dual vaccination for bovine respiratory syncytial virus and *Haemophilus somnus* on immune responses. *Vaccine* 2006;24:6018–27.
52. Grissett GP, White BJ, Larson RL. Structured literature review of responses of cattle to viral and bacterial pathogens causing bovine respiratory disease complex. *J Vet Intern Med* 2015;29:770–80.
53. Vanden Bush TJ, Rosenbusch RF. Characterization of the immune response to *Mycoplasma bovis* lung infection. *Vet Immunol Immunopathol* 2003;94:23–33.
54. Le Grand D, Solsona M, Rosengarten R, et al. Adaptive surface antigen variation in *Mycoplasma bovis* to the host immune response. *FEMS Microbiol Lett* 1996;144:267–75.

55. Toussaint JF, Coen L, Letellier C, et al. Genetic immunisation of cattle against bovine herpesvirus 1: glycoprotein gD confers higher protection than glycoprotein gC or tegument protein VP8. *Vet Res* 2005;36:529–44.
56. Ni H, Jia XX, Wang J, et al. Mapping a highly conserved linear neutralizing epitope at the N-terminus of the gD glycoprotein of bovine herpesvirus type 1 using a monoclonal antibody. *Microb Pathog* 2019;138:103815.
57. Wang X, Bi Y, Ran X, et al. Mapping a highly conserved linear neutralizing epitope on gD glycoprotein of bovine herpesvirus type 1 using a monoclonal antibody. *J Vet Med Sci* 2019;81:780–6.
58. Kalaycioglu AT, Russell PH, Howard CR. The characterization of the neutralizing bovine viral diarrhoea virus monoclonal antibodies and antigenic diversity of E2 glycoprotein. *J Vet Med Sci* 2012;74:1117–20.
59. Kimman TG, Westenbrink F, Schreuder BE, et al. Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies. *J Clin Microbiol* 1987;25:1097–106.
60. Zhang B, Chen L, Silacci C, et al. Protection of calves by a prefusion-stabilized bovine RSV F vaccine. *NPJ Vaccines* 2017;2:7.
61. Jutila MA, Holderness J, Graff JC, et al. Antigen-independent priming: a transitional response of bovine gammadelta T-cells to infection. *Anim Health Res Rev* 2008;9:47–57.
62. McGill JL, Rusk RA, Guerra-Maupome M, et al. Bovine gamma delta T cells contribute to exacerbated IL-17 production in response to co-infection with bovine RSV and *Mannheimia haemolytica*. *PLoS One* 2016;11:e0151083.
63. Mathy NL, Mathy JP, Lee RP, et al. Pathological and immunological changes after challenge infection with *Pasteurella multocida* in naive and immunized calves. *Vet Immunol Immunopathol* 2002;85:179–88.
64. Endsley JJ, Quade MJ, Terhaar B, et al. BHV-1-Specific CD4+, CD8+, and gammadelta T cells in calves vaccinated with one dose of a modified live BHV-1 vaccine. *Viral Immunol* 2002;15:385–93.
65. Siffow RM, Degel PM, Harmsen AG. Bronchoalveolar immune defense in cattle exposed to primary and secondary challenge with bovine viral diarrhoea virus. *Vet Immunol Immunopathol* 2005;103:129–39.
66. McGill JL, Nonnecke BJ, Lippolis JD, et al. Differential chemokine and cytokine production by neonatal bovine gammadelta T-cell subsets in response to viral toll-like receptor agonists and in vivo respiratory syncytial virus infection. *Immunology* 2013;139:227–44.
67. Taylor G, Thomas LH, Wyld SG, et al. Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. *J Virol* 1995;69:6658–64.
68. Hermeyer K, Buchenau I, Thomasmeyer A, et al. Chronic pneumonia in calves after experimental infection with *Mycoplasma bovis* strain 1067: characterization of lung pathology, persistence of variable surface protein antigens and local immune response. *Acta Vet Scand* 2012;54:9.
69. Gao Y, Wang C, Splitter GA. Mapping T and B lymphocyte epitopes of bovine herpesvirus-1 glycoprotein B. *J Gen Virol* 1999;80(Pt 10):2699–704.
70. Tikoo SK, Campos M, Popowich YI, et al. Lymphocyte proliferative responses to recombinant bovine herpes virus type 1 (BHV-1) glycoprotein gD (gIV) in immune cattle: identification of a T cell epitope. *Viral Immunol* 1995;8:19–25.
71. Gaddum RM, Cook RS, Furze JM, et al. Recognition of bovine respiratory syncytial virus proteins by bovine CD8+ T lymphocytes. *Immunology* 2003;108:220–9.
72. Woolums AR, Gunther RA, McArthur-Vaughan K, et al. Cytotoxic T lymphocyte activity and cytokine expression in calves vaccinated with formalin-inactivated

- bovine respiratory syncytial virus prior to challenge. *Comp Immunol Microbiol Infect Dis* 2004;27:57–74.
73. Collen T, Carr V, Parsons K, et al. Analysis of the repertoire of cattle CD4(+) T cells reactive with bovine viral diarrhoea virus. *Vet Immunol Immunopathol* 2002;87:235–8.
 74. Hodgson PD, Aich P, Manuja A, et al. Effect of stress on viral-bacterial synergy in bovine respiratory disease: novel mechanisms to regulate inflammation. *Comp Funct Genomics* 2005;6:244–50.
 75. Griebel P, Hill K, Stookey J. How stress alters immune responses during respiratory infection. *Anim Health Res Rev* 2014;15:161–5.
 76. Emam M, Livernois A, Paibomesai M, et al. Genetic and epigenetic regulation of immune response and resistance to infectious diseases in domestic ruminants. *Vet Clin North Am Food Anim Pract* 2019;35:405–29.
 77. Casas E, Garcia MD, Wells JE, et al. Association of single nucleotide polymorphisms in the ANKRA2 and CD180 genes with bovine respiratory disease and presence of *Mycobacterium avium* subsp. *paratuberculosis*(1). *Anim Genet* 2011;42:571–7.
 78. Glass EJ, Baxter R, Leach RJ, et al. Genes controlling vaccine responses and disease resistance to respiratory viral pathogens in cattle. *Vet Immunol Immunopathol* 2012;148:90–9.
 79. Neupane M, Kiser JN, Neiberghs HL, et al. Gene set enrichment analysis of SNP data in dairy and beef cattle with bovine respiratory disease. *Anim Genet* 2018;49:527–38.
 80. Chen J, Yang C, Tizioto PC, et al. Expression of the bovine NK-lysin gene family and activity against respiratory pathogens. *PLoS One* 2016;11:e0158882.
 81. Chen J, Huddleston J, Buckley RM, et al. Bovine NK-lysin: copy number variation and functional diversification. *Proc Natl Acad Sci U S A* 2015;112:E7223–9.
 82. Dassanayake RP, Falkenberg SM, Briggs RE, et al. Antimicrobial activity of bovine NK-lysin-derived peptides on bovine respiratory pathogen *Histophilus somni*. *PLoS One* 2017;12:e0183610.
 83. Dassanayake RP, Falkenberg SM, Register KB, et al. Antimicrobial activity of bovine NK-lysin-derived peptides on *Mycoplasma bovis*. *PLoS One* 2018;13:e0197677.
 84. Caverly JM, Diamond G, Gallup JM, et al. Coordinated expression of tracheal antimicrobial peptide and inflammatory-response elements in the lungs of neonatal calves with acute bacterial pneumonia. *Infect Immun* 2003;71:2950–5.
 85. Vulikh K, Bassel LL, Sergejewich L, et al. Effect of tracheal antimicrobial peptide on the development of *Mannheimia haemolytica* pneumonia in cattle. *PLoS One* 2019;14:e0225533.
 86. Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. *Science* 2016;352:aaf1098.
 87. Nickell JS, Keil DJ, Settje TL, et al. Efficacy and safety of a novel DNA immunostimulant in cattle. *Bov Pract (Stillwater)* 2016;50:9–20.
 88. Rogers KC, Miles DG, Renter DG, et al. Effects of delayed respiratory viral vaccine and/or inclusion of an immunostimulant on feedlot health, performance, and carcass merits of auction-market derived feeder heifers. *Bov Pract (Stillwater)* 2016;50:154–62.
 89. Woolums AR, Karisch BB, Parish JA, et al. Effect of a DNA-based immunostimulant on growth, performance, and expression of inflammatory and immune mediators in beef calves abruptly weaned and introduced to a complete ration. *J Anim Sci* 2019;97:111–21.

90. Ilg T. Investigations on the molecular mode of action of the novel immunostimulator ZelNate: activation of the cGAS-STING pathway in mammalian cells. *Mol Immunol* 2017;90:182–9.
91. Nosky B, Biwer J, Alkemade S, et al. Effect of a non-specific immune stimulant (Amplimune™) on the health and production of light feedlot calves. *J Dairy Vet Anim Res* 2017;6:00179.